Skip to main content
Blood logoLink to Blood
. 2014 Mar 6;123(10):1621. doi: 10.1182/blood-2014-01-552653

Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100-2105.

PMCID: PMC3945870

On page 2103 in the 1 March 2012 issue, there are errors for 7 percentages in Table 2. The errors likely arose from using the wrong denominator in the calculations. However, the absolute numbers do not change. Therefore, the data and consequent conclusions do not change. The correct table is shown.

Table 2.

Nonoverlapping classification of primary molecular cytogenetic abnormalities in MM

FISH abnormality Frequency (%) (N = 484)
Trisomy(ies) without IgH abnormality 201 (42)
IgH abnormality without trisomy(ies) 146 (30)
 t(11;14) 74 (15)
 t(4;14) 28 (6)
 t(14;16) 19 (4)
 t(14;20) 1 (<1)
 Unknown partner/deletion of IgH region 24 (5)
IgH abnormality with trisomy(ies) 74 (15)
 t(11;14) 12 (3)
 t(4;14) 19 (4)
 t(14;16) 5 (1)
 t(6;14) 3 (<1)
 Unknown partner/deletion of IgH region 35 (7)
Monosomy 14 in absence of IgH translocations or trisomy(ies) 22 (4.5)
Other cytogenetic abnormalities in absence of IgH translocations or trisomy(ies) or monosomy 14* 26 (5.5)
Normal 15 (3)
*

These included primarily monosomy 13 and p53 abnormalities.


Articles from Blood are provided here courtesy of The American Society of Hematology

RESOURCES